Risk-Adjusted Cancer Screening and Prevention (RiskAP): Integrating Prediction and Generation of Evidence in Digital Medicine

Final Meeting of the RiskAP Expert Group

In recent years, numerous risk factors for solid tumors have been identified. The focus here is on genetic changes that are hereditary and, according to current projections, are responsible for around one third of breast and colorectal cancer. These can be tested using multigene tests, which are now readily available in many EU countries. However, the interpretation of genetic information on risk prediction and clinical prediction programs based on it have not yet been sufficiently scientifically evaluated. It is still unclear whether risk-adjusted preventive measures actually reduce the mortality rate and to what extent they have a positive effect on the quality of life of those affected.
 
This discrepancy between the diagnostic offer and the evidence of clinical measures based on it requires new concepts. Since 2015, the international expert group on risk-adjusted prevention RiskAP has therefore been dealing intensely with the medical, ethical and legal challenges of genetic testing. The interdisciplinary project, funded by the German Federal Ministry of Health (BMG), aims to develop a conceptual framework and set international standards that address the manifold challenges in the field of early detection and prevention of hereditary tumors using breast cancer as an example.
 
At the conference, the group will present its findings and recommendations to the public and engage in discussion. The conference will be held in English.

Program